Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
RESEARCH TRIANGLE PARK, N.C., Nov. 21, 2016 -- G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that preliminary clinical data from its lead CDK4/6 inhibitor G1T28 for patients with small-cell lung cancer (SCLC) will be presented at the International Association for the Study of Lung Cancer’s 17th World Conference on Lung Cancer (WCLC), to be held December 4 – 7 at the Messe Wien Exhibition & Congress Center in Vienna, Austria. Details on the poster are as follows:
Title: G1T28, a Cyclin Dependent Kinase 4/6 Inhibitor, in Combination with Topotecan for Previously Treated Small Cell Lung Cancer: Preliminary Results
Poster Session: PS01
Poster Number: P1.07-002
Date / Time: Monday, December 5, 2:30 p.m. – 3:45 p.m. CET
Location: Hall B of the Messe Wien Exhibition & Congress Center
Presenter: Lowell L. Hart, M.D., Florida Cancer Specialists, Fort Myers, FL
G1 will also present preclinical data on G1T28 in a poster session at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, to be held November 29 – December 2 at the Internationales Congress Center Munich in Munich, Germany. Details on the poster are as follows:
Title: G1T28, a CDK4/6 inhibitor, preserves T lymphocyte function from damage by cytotoxic chemotherapy
Poster Session: Molecular targeted agents II
Poster Number: P118
Date / Time: Thursday, December 1, 10:15 a.m. – 5 p.m. CET
Location: The Exhibition Hall of Internationales Congress Center Munich
Presenter: Patrick J. Roberts, Ph.D., Pharm.D., Director of Translational Medicine, G1 Therapeutics
About G1T28
G1T28 is a potential first-in-class, short-acting IV CDK4/6 inhibitor being developed to preserve hematopoietic stem cells and enhance immune system function during chemotherapy. G1T28 is being studied in two Phase 1b/2a proof-of-concept trials in patients with small-cell lung cancer: a study in newly diagnosed, treatment-naive patients (NCT02499770), and a study in previously treated patients (NCT02514447).
About G1 Therapeutics, Inc.
G1 Therapeutics is a clinical-stage oncology company developing novel, small-molecule therapies that address significant unmet needs in people with cancer. The company is advancing a pipeline of potential best-in-class and first-in-class drug candidates in multiple oncology indications. G1 is privately held and based in Research Triangle Park, NC.
Visit www.g1therapeutics.com for more information.
Contact: Mark Velleca, MD, PhD G1 Therapeutics 919-213-9838 [email protected] Media: Laura Bagby 6 Degrees Communications 312-448-8098 [email protected]
